Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H31N3O5.H2O |
| Molecular Weight | 435.5139 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O
InChI
InChIKey=JQRZBPFGBRIWSN-YOTVLOEGSA-N
InChI=1S/C22H31N3O5.H2O/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26;/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28);1H2/t17-,18-,19-;/m0./s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C22H31N3O5 |
| Molecular Weight | 417.4986 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7700063 | https://www.ncbi.nlm.nih.gov/pubmed/1532534
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7700063 | https://www.ncbi.nlm.nih.gov/pubmed/1532534
Cilazapril (Vascace and Dynorm are brand names in a number of European countries) is an angiotensin converting enzyme (ACE; kininase II) inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Cilazapril is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. The half-life (30–50 hours) of cilazapril allows for once daily dosing unless the hypertension is severe. Cilazapril is used for the treatment of hypertension, congestive heart failure, post-myocardial infarction, and some other indications. Adverse events were mostly observed within the first 8-16 weeks of treatment, with headache, dizziness, fatigue, nausea, cough and chest pain being the most frequent.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1808 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Vascace Approved UseVascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure.
It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure. |
|||
| Primary | Vascace Approved UseVascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure.
It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19.08 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
38.71 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
52.76 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
47.52 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
51.18 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
38.57 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.81 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
26.26 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
20.03 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
22.47 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.83 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
33.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
82.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
182 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
37.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
94.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
40.09 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
131 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
319 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
239 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
210 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
99 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
89 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
507 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
313 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
255 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
102 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527539/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
52.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
99.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
256 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
496 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
42.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
79.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
175 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
342 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.1 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRIL ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
48.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
39.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
38.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
35.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2527533/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILAZAPRILAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 mg single, oral Higher than recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
Other AEs: Lightheadedness... |
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Lightheadedness | grade 1, 25% | 20 mg single, oral Higher than recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. | 2009-12 |
|
| Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. | 2008-11 |
|
| Impact of cilazapril on fibrinolytic system in hypertensive patients. | 2008-01 |
|
| Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis. | 2006-10 |
|
| [A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension]. | 2004-09 |
|
| Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy. | 2004 |
|
| The acute effects of cilazapril on pulmonary function tests and arterial blood gas changes in patients with pulmonary hypertension. | 2003 |
|
| Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure. | 2002-11 |
|
| [Effect of cilazapril on insulin sensitivity in patients with essential arterial hypertension]. | 2002-01-19 |
|
| Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucinations. | 2001-12 |
|
| Angiotensin-converting enzyme inhibitor cilazapril suppresses expression of basic fibroblast growth factor messenger ribonucleic acid and protein in endothelial and intimal smooth muscle cells in a vascular injury model of spontaneous hypertensive rats. | 1998-05 |
|
| [Follow-up of patients with chronic aortic valve insufficiency with ACE inhibitor therapy]. | 1997-12 |
|
| Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. | 1997-04 |
|
| Improvement of left ventricular diastolic dysfunction in hypertensive patients 1 month after ACE inhibition therapy: evaluation by ultrasonic automated boundary detection. | 1996 |
|
| Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. | 1995-12 |
|
| Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. | 1995-11 |
|
| Short term safety assessment of cilazapril. | 1993-11-24 |
|
| Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. | 1992-11 |
|
| Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study. | 1991 |
|
| Improvement of diastolic filling in hypertensive patients treated with cilazapril. | 1991 |
|
| Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients. | 1989 |
|
| A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. | 1989 |
|
| Antihypertensive and renal effects of cilazapril and their reversal by angiotensin in renovascular hypertensive rats. | 1988-04 |
|
| Effects of nitrendipine and cilazapril alone or in combination on hemodynamics and regional blood flows in conscious spontaneously hypertensive rats. | 1988 |
|
| Enzyme immunoassay discrimination of a new angiotensin-converting enzyme (ACE) inhibitor, cilazapril, and its active metabolite. | 1987-03 |
|
| Cilazapril prevents hypertension in spontaneously hypertensive rats. | 1986-05-01 |
|
| Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. | 1986-01-01 |
Sample Use Guides
Swallow each tablet with a drink of water. It does not matter what time of day you take yablet. However, always take it around the same time. Tablet may be taken before or after a meal.
High blood pressure (hypertension): The usual starting dose for adults is 1 mg per day.
Chronic heart failure: The usual starting dose is 0.5 mg per day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:51 GMT 2025
by
admin
on
Mon Mar 31 17:54:51 GMT 2025
|
| Record UNII |
19KW7PI29F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
56329
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
3698
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
C76133
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
m3545
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | Merck Index | ||
|
145568
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
92077-78-6
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
DB01340
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
SUB16409MIG
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
DTXSID00238846
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
W-122
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY | |||
|
19KW7PI29F
Created by
admin on Mon Mar 31 17:54:51 GMT 2025 , Edited by admin on Mon Mar 31 17:54:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CILAZAPRILAT IS EP IMPURITY B OF CILAZAPRIL
|
||
|
IMPURITY -> PARENT |
|
![Structure of 1,1-Dimethylethyl (1S,9S)-9-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate](/img/f8868d41-85cb-4cc7-802d-cd0638d7d99c.svg "Structure of 1,1-Dimethylethyl (1S,9S)-9-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate")